Crossref
2288P PSMA-REACH: Real-world effectiveness and safety of [177Lu]Lu-PSMA-617 in patients with mCRPC
Annals of Oncology · 2026-12 · 37 · S1354
DOI: 10.1016/j.annonc.2026.08.2575 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Oncology, 2026-12. Verfasst von P. Barthelemy und 9 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Barthelemy, P., Roubaud, G., Flechon, A., Giraudet, A., Blanchard, P., Fiard, G., Pouriel, M., Duperray, E., Courbon, F., & Bailly, C. (2026). 2288P PSMA-REACH: Real-world effectiveness and safety of [177Lu]Lu-PSMA-617 in patients with mCRPC. Annals of Oncology, 37, S1354. https://doi.org/10.1016/j.annonc.2026.08.2575
Vancouver
Barthelemy P, Roubaud G, Flechon A, Giraudet A, Blanchard P, Fiard G, et al. 2288P PSMA-REACH: Real-world effectiveness and safety of [177Lu]Lu-PSMA-617 in patients with mCRPC. Annals of Oncology. 2026;37:S1354. doi:10.1016/j.annonc.2026.08.2575
BibTeX
@article{Barthelemy2026,
author = {Barthelemy, P. and Roubaud, G. and Flechon, A. and Giraudet, A-L. and Blanchard, P. and Fiard, G. and Pouriel, M. and Duperray, E. and Courbon, F. and Bailly, C.},
title = {2288P PSMA-REACH: Real-world effectiveness and safety of [177Lu]Lu-PSMA-617 in patients with mCRPC},
journal = {Annals of Oncology},
year = {2026},
volume = {37},
pages = {S1354},
doi = {10.1016/j.annonc.2026.08.2575}
}
EUVIMED